Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Financial Performance of Jasper Therapeutics for the Year Ending December 31 2023

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Jasper Therapeutics recorded a net loss of $16.6 million and $64.5 million for the three months and the year ended on December 31, 2023, respectively. The basic and diluted net loss per share for common stockholders were $1.50 and $6.18 during the same periods. The company’s cash and cash equivalents totaled $86.9 million as of December 31, 2023. Research and development expenses for the year ended December 31, 2023, amounted to $51.8 million, with stock-based compensation expenses of $1.6 million included. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

—

On March 4, 2024, Jasper Therapeutics reported a net loss of $16.6 million and $64.5 million for the three months and the year ending on December 31, 2023. The basic and diluted net loss per share attributable to common stockholders were $1.50 and $6.18 for the same periods. Moreover, the company’s cash and cash equivalents as of December 31, 2023, were reported at $86.9 million. Research and development expenses for the year ending December 31, 2023, were $51.8 million, which included stock-based compensation expenses of $1.6 million. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

[bs_slider_forecast ticker=”JSPR”]

JSPR Stock Shows Strong Performance with Positive Price Momentum in Pre-Market Trading

On March 4, 2024, JSPR stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock. The price of JSPR shares had increased by $0.83 since the market last closed, representing a 3.91% rise. In pre-market trading on March 4, the stock had risen by an additional $0.67. This strong performance suggests that investors have confidence in JSPR and are optimistic about its future prospects. It is important for investors to continue monitoring JSPR stock and staying informed about any news or developments that may impact its performance.

Currently Playing

JSPR Stock Performance Review: Mixed Data Leaves Investors Uncertain on March 4, 2024

On March 4, 2024, investors in JSPR stock may have been feeling uncertain about the company’s financial performance based on the available data. According to CNN Money, JSPR’s total revenue information was currently unavailable, leaving investors without a key indicator of the company’s financial health.

The data that was available showed that JSPR had experienced a decrease in net income over the past year. The company reported a net income of -$37.69 million for the past year, which was a 23.0% decrease from the previous year. In the most recent quarter, JSPR reported a net income of -$17.54 million, representing a 9.1% decrease from the previous quarter.

Despite the decrease in net income, there was a glimmer of hope for investors in the form of earnings per share (EPS) data. JSPR reported an EPS of -$10.33 for the past year, which actually represented a 61.59% increase from the previous year. However, in the most recent quarter, the company reported an EPS of -$1.60, which was an 8.61% decrease from the previous quarter.

Overall, the mixed performance data for JSPR on March 4, 2024, may have left investors feeling uncertain about the company’s future prospects. While the increase in EPS over the past year was a positive sign, the decreases in net income over the same period could be cause for concern. Without more information on the company’s total revenue, investors may have been left wondering about JSPR’s overall financial health and future performance.

[stock_market_chart symbol=”JSPR” range=”3mo” interval=”1d” settings='{“primaryChartType”:”smoothedLine”,”secondaryChartType”:”column”,”width”:”100%”,”height”:”500px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:14,”color”:”#383838″,”primaryLineColor”:”#5679ff”,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#5679ff”,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#020202″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#e8e8e8″,”scrollbarSelectedBackgroundColor”:”#f7f7f7″,”scrollbarGraphFillColor”:”#435dc2″,”scrollbarSelectedGraphFillColor”:”#92a8fc”,”primaryLineThickness”:2,”secondaryLineThickness”:1,”gridThickness”:1,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”searchMode”:”search”,”mouseWheelZoomEnabled”:false,”cursorEnabled”:true,”exportEnabled”:true,”scrollbarEnabled”:true,”legendEnabled”:true,”periods”:”1D,1M,YTD,ALL”,”defaultPeriod”:”1M”}’]

Tags: JSPR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ projections

Financial Analysts Bullish on Li Auto Stock

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Lyfts Stock Rises After Upgrade from RBC Capital

Pharmaceutical Markets and money

Analyst Raghuram Selvaraju Reiterates Buy Rating for BridgeBio Pharma with 47 Price Target

Recommended

Red Cat Stock

Red Cat Shares Face Turbulence After Stellar Rally

4 months ago

PHX Minerals Exceeds Q1 Earnings Expectations Despite Revenue Decline

2 years ago
Elanco Animal Health Stock

Indianapolis Emerges as Animal Health Innovation Hub Through Elanco’s Strategic Move

5 months ago
Home Construction Stock Exchange

Analyzing Southland Holdings Q4 Earnings Performance

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

NCR Voyix Charts a Course Toward Cloud-Centric Growth

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

Solana Faces Billions in Potential Token Supply Releases

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

Trending

iRobot Stock
Mergers & Acquisitions

iRobot Exits Public Markets Following Bankruptcy and Acquisition

by Dieter Jaworski
February 5, 2026
0

The restructuring of iRobot under Chapter 11 bankruptcy protection has concluded, resulting in the company's delisting from...

Exxon Mobil Stock

Exxon Mobil Charts a New Course with Major Carbon Capture Initiative

February 5, 2026
CrowdStrike Stock

CrowdStrike Shares Face Headwinds Amid Mixed Signals

February 5, 2026
NCR Stock

NCR Voyix Charts a Course Toward Cloud-Centric Growth

February 5, 2026
Rolls Royce Stock

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • iRobot Exits Public Markets Following Bankruptcy and Acquisition
  • Exxon Mobil Charts a New Course with Major Carbon Capture Initiative
  • CrowdStrike Shares Face Headwinds Amid Mixed Signals

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com